Is High Protein Aging Your Patients?

Protein is back in the news and patients are asking questions. A comprehensive review of more than 350 papers has reignited a crucial dietary debate: is high protein intake harming our patients' long-term metabolic health? Responding effectively requires bridging the gap between two competing priorities: safeguarding long-term metabolic health and preventing age-related muscle loss.

Valter Longo mirrors the standard US Dietary Guidelines, placing healthy adults under 65 at 0.7 to 0.8 g/kg (rising to ~1.0 after 65). Dr. Stacy Sims advocates for 1.7 to 2.4 g/kg for active and midlife women fighting lean muscle loss. For a 75 kg woman, that’s the difference between 60 grams a day (think about three eggs and a chicken breast) and 165 grams (which requires active meal planning with shakes, Greek yogurt, and double the protein).

Longo's rests on a 2014 Cell Metabolism analysis of 6,381 NHANES III adults aged 50 and over, followed up to 18 years. Those in the highest protein group, above 20% of calories, had four times the cancer mortality of the lowest group, an effect the authors compared to smoking. The proposed mechanism is IGF-1 and mTOR signaling. The finding reversed after 65, where higher intake tracked with lower mortality.

Sims's case rests on the exercise and trial literature. Muscle in peri- and post-menopausal women becomes anabolically resistant, demanding a larger protein dose per meal to trigger synthesis. Don Layman's work put the leucine threshold near 2.5 grams, roughly 30 grams of quality protein. Randomized trials from Stuart Phillips's lab and others show higher protein improving lean mass alongside triglycerides, blood pressure, and fasting insulin. Attia's stated position is that sarcopenia is a concrete risk and mTOR activation is a theoretical one.

Both camps already concede that age moves the number. Longo raises his after 65. Sims scales hers up during perimenopause and high training loads. Their disagreement lives in the 50-to-65 window, and that window holds a large share of most panels in this field.

The new review, from Bailey Knopf and Dudley Lamming at Wisconsin-Madison, introduces a second variable: whether the body is training. In someone doing resistance exercise, dietary amino acids are pulled into muscle repair. In someone sedentary, the same leucine load keeps nutrient-sensing pathways switched on with no repair demand to absorb it. Over time, this constant overload can cause cellular stress, accelerating cellular aging (senescence) and promote metabolic dysfunction. Lamming's work reinforces what functional and longevity medicine clinicians already practice: moving past one-size-fits-all RDA targets in favor of hyper-personalized nutrition scaled to physical activity, metabolic health, and real-time physiological demand.

Hold the two evidence bases against that variable and something useful appears. Longo's data comes from a 24-hour dietary recall in a general population sample, which cannot separate high protein from high protein without training. The loading camp's trials nearly all delivered protein alongside resistance exercise. The meta-analysis of 36 trials in 1,682 nonfrail older adults is the tell: with supplementation alone, lean mass, grip strength, gait speed, and chair-rise ability all came out flat.

So the two camps may have been describing different patients the whole time.

Worth stating the limits before quoting any of this to a patient. The new review is mechanistic, its lifespan data is animal, and no human trial has shown that protein restriction extends life. Longo's mortality finding is observational. Neither side of this argument has the trial it would need.

Training status becomes the sorting question, ahead of age and well ahead of weight.

For a sedentary 54-year-old, Longo's cohort is the population that resembles her, and prescribing 2 g/kg means applying trial evidence generated in people who were lifting. For a 68-year-old doing resistance work twice a week, the loading camp's evidence applies directly and her number stands. The decision path below is the version worth keeping near the desk.

Which means a protein target should leave the room with a training plan attached to it. Where the training plan is empty, the target belongs closer to demand than to aspiration, and the first thing to fix is the empty plan.

The patient where this bites hardest is the sedentary one on a GLP-1. In older adults losing weight intentionally, 25% to 33% of what comes off is fat-free mass, which is why protocols push protein hard on this group. Keep pushing it. Then look at whether anything is asking that protein to build.

In the SEMALEAN study, lean mass fell about 3 kg by month seven and then held, and sarcopenic obesity dropped from 49% of patients to 33% at a year. Body composition can improve on these drugs when something is asking the muscle to stay.

And for the frail, the argument runs backward. Doug Kalman of Substantiation Sciences, responding to the review, made the case that "too little is the clearer and more common risk in aging: chronically low intake accelerates sarcopenia, frailty and loss of functional independence." For a frail 78-year-old he is right and the review barely applies.

Be a modern clinician with the help of Ultralight, the AI-native EHR built specifically for functional, integrative, and longevity medicine. We’ve recently launched wearables integrations and improved AI-native clinical workflows - get in touch to see the latest updates.

As a physician, you probably didn’t spend much training in how to build an audience, navigate your personal brand and communicate a story. But in today’s world, meeting patients where they are involves venturing into social media. There are many reasons why this is becoming an increasingly important skill - and the one that feels the most painful at times.

On Wednesday, August 12 at 12:00 PM ET, Sunita Mohanty sits down with Dr. Hillary Lin, a Stanford-trained internist and co-founder of CareCore for a candid conversation on building a brand as a physician: why she started posting, what she has tried, and what has actually worked.

Register here for free.

An FDA advisory panel voted to loosen compounding rules on six peptides, against its own staff's recommendation. On July 23 and 24 the Pharmacy Compounding Advisory Committee backed BPC-157, TB-500, MOTS-C, KPV and others for the 503A bulk drug substances list, voting against FDA staff's written recommendation six consecutive times. The 8-6 vote is advisory only, and formal rulemaking comes next. Access may widen well before the evidence base does, so the counseling conversation matters more than the supply question.

FDA cleared the first patient-facing large language model as a medical device. UpDoc's platform came out of a Stanford-led trial and is deploying at Cleveland Clinic, Allegheny Health Network, and UCSF, with clinician review before any prescription is finalized. The regulatory line just moved from AI that advises us to AI that talks to our patients, and that review requirement is the part worth reading closely.

Sleep duration maps onto biological age as a U-shaped curve, not a straight line. Using imaging, proteomics, and metabolomics across 23 aging clocks in the UK Biobank, researchers found the lowest biological age gaps between 6.4 and 7.8 hours, varying by organ and by sex, with both short and long sleep tracking to higher systemic disease risk. Useful with the patient optimizing down to six hours, and a caution against treating more sleep as linearly better.

Upcoming Conferences & Events

Sept 22–23, MVMNT Longevity Medicine Summit · Coronado, CA · Evidence-graded longevity science, hands-on labs, and clinical frameworks you can implement the week after. Capped at 300 clinicians. Ultralight will be there!

Oct 8–10, A4M Women's Health Summit · San Antonio, TX ·  The best clinical education on hormone, metabolic, and midlife women's health you will see this year. The room to be in if you are growing the perimenopause and menopause side of your practice.

Oct 21–24, NAMS Annual Meeting · San Diego, CA  · The single most practice-changing meeting of the year for midlife women's health. Your protocols will look different after this one.

Nov 5–8, Eudēmonia Summit · West Palm Beach, FL ·  One of the most talked-about longevity gatherings in the U.S. Experientials, hands-on demos, and the best place to try the emerging frameworks your patients will ask you about next year. OvationLab and Ultralight will be there!

Nov 5-7, Private Physicians Alliance Annual Meeting · St. Petersburg, FL · The gathering for independent, cash-pay, and concierge physicians navigating practice independence. Practical and peer-driven. Ultralight will be there!

Nov 8-11, American College of Lifestyle Medicine Conference · Orlando, FL · Lifestyle medicine's main annual event — evidence-based approaches to behavior change, chronic disease, and healthspan. Growing overlap with the longevity medicine community.

Dec 11–13, A4M Longevity Fest · Las Vegas, NV  · The biggest longevity event in the U.S. The room spans clinicians, industry, founders, and the people building next year's platforms, and the connections from this one tend to compound through the rest of your year. OvationLab and Ultralight will be there!

Know of an event we should add? Reply and tell us.

Two respected camps have been three-fold apart on protein for a decade, and both were reading real evidence. What this review adds is the variable that may explain the gap: one side studied people who train, the other studied people who mostly do not. The patient in front of us belongs to one of those populations, and knowing which one is now part of the prescription.

Reply and tell us how you capture training status today, or whether you capture it at all. The best ideas in this newsletter come from clinicians doing the work.

Until next Thursday, keep building the practice you imagined when you started.

— Dr. G and Sunita